Go back

Funding boost for Alzheimer’s drugs

The Innovative Medicines Initiative has launched a €53-million project to test clinical trials for drugs to treat Alzheimer’s disease.

The announcement was made on 11 December, at the same time as the G8 summit on dementia, taking place in London. The fund is made up of €28m from the European Commission’s Framework 7, and the remainder is from in-kind contributions by the pharmaceutical companies in the project.

IMI wants to developing a novel, flexible approach to clinical trials, which could speed up the drug development process by allowing companies and researchers to run multiple proof-of-concept studies simultaneously, a statement explained. The idea is for 20 per cent of patients to be in a placebo group, compared with 50 per cent in conventional trials.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.